Please assess the completion status of the following clinical trial:

Trial Title: RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of biliary tract adenocarcinoma/cholangiocarcinoma~* Must have locally advanced or distant metastatic disease that is not surgically curable~* Failed first-line chemotherapy~* Age ≥ 18 years~* Life expectancy of at least 12 weeks (3 months)~* Performance status 0 or 1~* Adequate liver, kidney, and bone marrow function~Exclusion Criteria:~* Symptomatic metastatic brain or meningeal tumors~* Investigational compound within 4 weeks of enrollment~* History of needing to permanently discontinue prior gemcitabine/ cisplatin regimen for reasons other than progression (i.e. toxicity)~* Any medical condition which, in the investigator's opinion, makes the patient unsuitable for participation~* Pregnant or nursing~* Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results~* Albumin \<2.8~* Uncontrolled or clinically relevant ascites~* Absolute contraindication for MRI imaging such as intracorporeal metal or pacemaker

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RRx-001 the cisplatin and gemcitabine (Type: EXPERIMENTAL): Patients with advanced and metastatic biliary tract adenocarcinoma (cholangiocarcinoma) who had been treated with and failed first-line chemotherapy will be treated with RRx-001 (20 mg) intravenously weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression

Based on this trial design, predict the completion outcome and termination type (if applicable).